Rituximab for the treatment of non-hodgkins lymphoma and chronic lymphocytic leukaemia

Drugs

Volumn 70, Issue 3, 2010, Pages 261-272

  Hagemeister, Fredrick ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Non Hodgkins lymphoma; Rituximab; Therapeutic use; Treatment

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; BICARBONATE; CARBOPLATIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; IFOSFAMIDE; INTERFERON; MEPREDNISONE; METHOTREXATE; MITOXANTRONE; OXALIPLATIN; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LARGE CELL LYMPHOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MONOTHERAPY; NONHODGKIN LYMPHOMA; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; RECURRENCE;

EID: 77249100894     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11532180-000000000-00000     Document Type: Review

References (68)

1. Olszewski AJ, ossbard ML. Empowering targeted ther-apy: lessons from rituximab [letter]. Sci STKE 2004 Jul; 2004: 241, e30.
2. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999 Feb; 93 (3): 1032-1037
3. Srinivas S, Yook C, Chang V, et al. Prevalence of bone marrow CD20 positivity in patients (pts) with multiple myeloma (MM) [abstract no. 2687]. J Clin Oncol 2001; 20 (Suppl.)
4. Treon SP, Kelliher A, Keele B, et al. Expression of sero-therapy target antigens in Waldenstrom's macro-globulinemia: therapeutic applications and considerations. Semin Oncol 2003 Apr; 30 (2): 248-252
5. Glennie MJ, French RR, Cragg MS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007 Sep; 44 (16): 3823-3837
6. Shan D, Ledbetter J, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998 Mar; 91 (5): 1644-1652
7. Shan D, Ledbetter J, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000 Mar; 48 (12): 673-683
8. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000 Apr; 26 (2): 133-143
9. Demidem A, Hanna N, Hariharan H, et al. Chimeric anti-CD20 antibody (IDEC C2B8) is apoptotic and sensitizes drug-resistant human B cell lymphomas to the cytotoxic effect of CDDP, VP-16 and toxins [abstract]. FASEB J 1996; 9 (Suppl.): A206
10. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the in-terleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001 Jul; 61 (13): 5137-5144
11. Alas S,Emmanouilides C,BonavidaB, et al. Inhibition ofIL-10 by Rituximab inactivates results in down-regulation of Bcl-2 and sensitization of B cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001 Mar; 7 (3): 709-723
12. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lym-phoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001 Sep; 114 (4): 800-809
13. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002 Jan; 87 (1): 33-43
14. National Comprehensive Cancer Network. NCCN-drugs & biologics compendium [online]. Available from URL:http://www.nccn.org/professionals/drug- compendium/con tent/contents.asp [Accessed 2009 Feb 17]
15. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, non-Hodgkin's lymphoma: V.I.2009 [online]. Available from URL: http://www.nccn. org/professionals/physician-gls/PDF/nhl.pdf [Accessed 2009 Feb 17]
16. Rituxan prescribing information [online]. Available from URL: http://www.gene.com/gene/products/information/ pdf/rituxan-prescribing.pdf [Accessed 2009 Feb 17]
17. European Medicine Agency. European public assessment report for MabThera [online]. Available from URL: http:// www.emea.europa.eu/humandocs/Humans/EPAR/ mabthera/ mabthera.htm [Accessed 2009 July 12]
18. Hornberger J, Reyes C, Lubeck D, et al. Economic evalua-tion of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymph 2008 Feb; 49 (2): 227-236
19. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincris-tine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005 Apr; 103 (8): 1644-1651
20. Hayslip JW, Simpson KN. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission. Clin Lymph Myel 2008 Jun; 8 (3): 166-170
21. Carr E, Lerner S, Rick Aultman R, et al. Treatment effect of first line rituximab, fludarabine and cyclophosphamide in a chronic lymphocytic leukemia patient cohort: an evaluation of prognostic factors, estimated life expectancy and economic outcomes [abstract no. 2396]. Blood (ASH Annual Meeting Abstracts) 2008; 112 (Suppl.)
22. American Cancer Society. Cancer facts and figures 2009 [online]. Available from URL: http://www.cancer.org/docroot/STT/ content/STT-1x-Cancer- Facts-Figures-2009.asp?from=fast [Accessed 2009 Jul 12]
23. Armitage JO. The changing classification of non-Hodgkin's lymphomas. CA Cancer J Clin 1997 Nov-Dec; 47 (6): 323-325
24. Cheson BD, Gregory SA, Marcus R. Emerging treatments for indolent lymphoma. Clin Adv Hematol Oncol 2007 May; 5 (5 Suppl.): 1-9
25. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007 May; 99 (9): 706-714
26. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cy-clophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005 Dec; 106 (12): 3725-3732
27. Salles G, Mounier N, de Guibert S, et al. Rituximab com-bined with chemotherapy and interferon in follicular lym-phoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008 Dec; 112 (13): 4824-4831
28. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007 May; 25 (15): 1986-1992
29. Marcus RE, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008 Oct; 26 (28): 4579-4586
30. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclopho-sphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory folli-cular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004 Nov; 104 (10): 3064-3071
31. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood 2006 Nov; 108 (10): 3295-3301
32. Ghielmini ME, Hsu Schmitz S, Martinelli G, et al. Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98 [abstract no. 8512]. J Clin Oncol 2009; 27 (15S Suppl.)
33. Hochster HS, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and pre-dnisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009 Apr; 27 (10): 1607-1614
34. Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non Hodgkin's lymphoma: a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005 Feb; 23 (6): 1088-1095
35. Forstpointner R, Unterhalt M, Dreyling M, et al. Main-tenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006 Dec; 108 (13): 4003-4008
36. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006 May; 7 (5): 379-391
37. Habermann TM, Weller EA, Morrison VA, et al. Ritux-imab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lym-phoma. J Clin Oncol 2006 Jul; 24 (19): 3121-3137
38. Coiffier B, Gisselbrecht C, Bosly A, et al. 10 years follow-up of the GELA LNH98.5 study, first randomized study comparing R-CHOP to CHOP chemotherapy in patients with diffuse large B-cell lymphoma [abstract no. 3741]. Blood (ASH Annual Meeting Abstracts) 2009; 114
39. van Oers MH. Rituximab maintenance therapy: a step for-ward in follicular lymphoma. Haematologica 2007 Jun; 92 (6): 826-832
40. Gisselbrecht C. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Haematology 2008 Dec; 143 (5): 607-621
41. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004 May; 103 (10): 3684-3688
42. Haioun C, Mounier N, Emile JF, et al. Rituximab compared to observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor-risk diffuse large B-cell lymphoma: updated results of the LNH98-B3 GELA study [abstract no. 8012]. J Clin Oncol 2007; 25 (15S Suppl.)
43. Gisselbrecht C, Glass B, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study [abstract no. 8509]. J Clin Oncol 2009; 27 (15S Suppl.)
44. Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymph Myel 2007 Dec; 8 Suppl. 2: 57S-62S
45. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008 Sep; 26 (27): 4473-4479
46. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008 Jun; 111 (12): 5446-5456
47. Johnson S, Smith AG, Loffler H, et al. Multicentre prospec-tive randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996 May; 347 (9013): 1432-1438
48. Leporrier M, Chevret S, Cazin B, et al. Randomized com-parison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001 Oct; 98 (8); 2319-2325
49. Byrd JC, Rai K, Peterson BL, et al. The addition of ritux-imab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005 Jan; 105 (1): 49-53
50. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008 Aug; 112 (4): 975-980
51. Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group [abstract no. 535]. Blood (ASH Annual Meeting Abstracts) 2009; 114
52. Wierda W, O'Brien S, Faderl S, et al. A retrospective com-parison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 2006 Jan; 106 (2): 337-345
53. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005 Jun; 23 (18): 4070-4078 (Pubitemid 46211312)
54. Robak T, Moiseev SI, Dmoszynska A, et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized Phase III REACH trial [abstract no. LBA-1]. Blood (ASH Annual Meeting Abstracts) 2008; 112
55. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003 Jan; 101 (1): 6-14
56. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lym-phocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003 May; 21 (9): 1746-1751
57. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001 Apr; 19 (8): 2153-2164
58. Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and flu-darabine in patients with chronic lymphocytic leukemia. Blood 2002 Nov; 100 (9): 3115-3120
59. Stilgenbauer S, Zenz T, Winkler D, et al. Genomic aberra-tions, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial [abstract no. 781]. Blood (ASH Annual Meeting Abstracts) 2008; 112
60. Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009 Mar; 8 (2): 223-235
61. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007 May;12 (5): 601-609
62. Horning SJ. Follicular lymphoma, survival, and rituximab: is it time to declare victory? J Clin Oncol 2008 Oct; 26 (28): 4537-4538
63. United States National Institutes of Health. Clinical Trials.gov. Rituximab clinical trials [online]. Available from URL: http://www. clinicaltrials.gov/ct2/results?term= rituximab [Accessed 2009 Jan 13]
64. Taverna CJ, Bassi S, Hitz F, et al. First results of long-term rituximab maintenance treatment in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03 [abstract no. 8534]. J Clin Oncol 2009; 27 (15S Suppl.)
65. Wenger MK, Foa R, Arcaini L, et al. Safety in patients re-ceiving maintenance rituximab for follicular lymphoma: results from the phase IIIb MAXIMA trial [abstract no. 8606]. J Clin Oncol 2008; 26 (15S Suppl.)
66. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the National LymphoCare Study. J Clin Oncol 2009 Mar; 27 (8): 1202-1208
67. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bend-amustine plus rituximab versus CHOP plus rituximab in the first-line-treatment of patients with follicular, indolent and mantle cell lymphomas: results of a randomized phase III study of the Study Group indolent Lymphomas (StiL) [abstract no. 2596]. Blood (ASH Annual Meeting Abstracts) 2008; 112
68. Fischer K, Stilgenbauer S, Schweighofer CD, et al. Bend-amustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG) [abstract no. 330]. Blood (ASH Annual Meeting Abstracts) 2008; 112